ArticleAging2021
Differentially expressed immune response genes in COVID-19 patients based on disease severity.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer.Pathogens (Basel, Switzerland) · 2025Article
- Study of immunological and inflammatory gene response in Indian cohort of COVID- 19 patients by NanoString technology.Immunologic research · 2025Article
- Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2025Review
- Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis.Scientific reports · 2024Article
- Abortive infection of bat fibroblasts with SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era.Molecular biology reports · 2024Article
- Featured immune characteristics of COVID-19 and systemic lupus erythematosus revealed by multidimensional integrated analyses.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Beauty and the beast: host microRNA-155 versus SARS-CoV-2.Human cell · 2023Review
- Circulating microRNAs as emerging regulators of COVID-19.Theranostics · 2023Review
- Differentially Expressed Inflammatory Cell Death-Related Genes and the Serum Levels of IL-6 are Determinants for Severity of Coronaviruses Diseases-2019 (COVID-19).Advanced biomedical research · 2023Article
- Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study.Iranian journal of medical sciences · 2023Article
- Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods.Biomolecules · 2022Article
- A machine learning approach utilizing DNA methylation as an accurate classifier of COVID-19 disease severity.Scientific reports · 2022Article
- Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A review.Virus research · 2022Review
- miRNA expression in COVID-19.Gene reports · 2022Review
- Article
- High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19.Clinical immunology (Orlando, Fla.) · 2022Article
- COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response.BMC infectious diseases · 2022Article
- microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Potential Predictive Value of miR-125b-5p, miR-155-5p and Their Target Genes in the Course of COVID-19.Infection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundDysregulated immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are thought to underlie the progression of coronavirus disease 2019 (COVID-19). We sought to further characterize host antiviral and cytokine gene expression in COVID-19 patients based on illness severity.
methodsIn this case-control study, we retrospectively analyzed 46 recovered COVID-19 patients and 24 healthy subjects (no history of COVID-19) recruited from the Second People's Hospital of Fuyang City. Blood samples were collected from each study participant for RNA extraction and PCR. We assessed changes in antiviral gene expression between healthy controls and patients with mild/moderate (MM) and severe/critical (SC) disease.
resultsWe found that type I interferon signaling (IFNA2, TLR8, IFNA1, IFNAR1, TLR9, IRF7, ISG15, APOBEC3G, and MX1) and genes encoding proinflammatory cytokines (IL12B, IL15, IL6, IL12A and IL1B) and chemokines (CXCL9, CXCL11 and CXCL10) were upregulated in patients with MM and SC disease. Moreover, we found that IFNA1, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), and Fas-associated protein with death domain (FADD) were significantly downregulated (
conclusionCOVID-19 is associated with the activation of host antiviral genes. Induction of the IFN system appears to be particularly important in controlling SARS-CoV-2 infection, as decreased expression of IFNA1, APOBEC3G and FADD genes in SC patients, relative to MM patients, may be associated with disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.